ModernMedicine Resource Center More Topics


FDA generics backlog improves, although criticism continuesWhile many groups are criticizing the FDA backlog of generic drug approvals, the agency has released the numbers on approvals and tentative approvals for 2015.
Generic treatment for chronic myeloid leukemia could save millionsFive years of imatinib treatment for CML = >$100,000 saved per patient.
Biosimilars' savings may reach $100 billion by 2020The use of biosimilars in the European Union and the United States may yield huge savings to healthcare systems over the next five years
U.S. physicians start to embrace prescribing of biosimilarsPhysicians are beginning to understand the value of biosimilars, particularly those who are high prescribers of biologics and therefore familiar with biosimilars.
Legislators call for transparency in generic drug pricingSixteen members of Congress are urging passage of the MAC Transparency Act and greater reimbursement transparency for the big federal health programs.
Biosimilar offers hope of lower-cost treatment of autoimmune diseasesHere's the latest on the second biosimilar in line to receive FDA approval.
Do chains or independent pharmacies offer the best generic pricing?
Do chains or independent pharmacies offer the best generic pricing?After secretly shopping at 200 stores in six states, "Consumer Reports" announced its findings, and they make for very interesting reading.
Generic drugs: How to keep those cost savings comingThe U. S. healthcare system saved a record $254 billion from generic drugs in 2014 and $1.68 trillion from 2005 to 2014, but much more can be done.
Any solutions to the sudden price spikes for generics?
Any solutions to the sudden price spikes for generics?A December 9 hearing of the U.S. Senate Special Committee on Aging had senators looking closely at several possible solutions to the recent, massive price spikes for particular generic drugs, including having FDA speed approval for competitors for products with no competition.
Senators target pay-for-delay pharma dealsU.S. Senators Amy Klobuchar (D-Minn.) and Chuck Grassley (R-Iowa) recently reintroduced legislation that would make it illegal for brand-name drug manufacturers to pay-off other drug manufacturers to keep generic versions of brand-name drugs off the market.